1-7 of 7
Luc Friboulet
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations

Jessica J. Lin, Joshua C. Horan, Anupong Tangpeerachaikul, Aurélie Swalduz, Augusto Valdivia, Melissa L. Johnson, Benjamin Besse, D. Ross Camidge, Toshio Fujino, Satoshi Yoda, Linh Nguyen-Phuong, Hayato Mizuta, Ludovic Bigot, Catline Nobre, Jii Bum Lee, Mi Ra Yu, Scot Mente, Yuting Sun, Nancy E. Kohl, James R. Porter, Matthew D. Shair, Viola W. Zhu, Enriqueta Felip, Byoung Chul Cho, Luc Friboulet, Aaron N. Hata, Henry E. Pelish, Alexander Drilon
Journal: Cancer Discovery
Cancer Discov OF1–OF20.
https://doi.org/10.1158/2159-8290.CD-24-0231
Published: 13 September 2024
View article titled, NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
Open the PDF for NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations in another window
Includes: Supplementary data
Journal Articles

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

Francesco Facchinetti, Antoine Hollebecque, Floriane Braye, Damien Vasseur, Yoann Pradat, Rastislav Bahleda, Cédric Pobel, Ludovic Bigot, Olivier Déas, Juan David Florez Arango, Giorgia Guaitoli, Hayato Mizuta, David Combarel, Lambros Tselikas, Stefan Michiels, Sergey I. Nikolaev, Jean-Yves Scoazec, Santiago Ponce-Aix, Benjamin Besse, Ken A. Olaussen, Yohann Loriot, Luc Friboulet
Journal: Cancer Discovery
Cancer Discov (2023) 13 (9): 1998–2011.
https://doi.org/10.1158/2159-8290.CD-22-1441
Published: 06 September 2023
View article titled, Resistance to Selective FGFR Inhibitors in <em>FGFR-</em>Driven Urothelial Cancer
Open the PDF for Resistance to Selective FGFR Inhibitors in <em>FGFR-</em>Driven Urothelial Cancer in another window
Includes: Supplementary data
Journal Articles

Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer

Yoann Pradat, Julien Viot, Andrey A. Yurchenko, Konstantin Gunbin, Luigi Cerbone, Marc Deloger, Guillaume Grisay, Loic Verlingue, Véronique Scott, Ismael Padioleau, Leonardo Panunzi, Stefan Michiels, Antoine Hollebecque, Gérôme Jules-Clément, Laura Mezquita, Antoine Lainé, Yohann Loriot, Benjamin Besse, Luc Friboulet, Fabrice André, Paul-Henry Cournède, Daniel Gautheret, Sergey I. Nikolaev
Journal: Cancer Discovery
Cancer Discov (2023) 13 (5): 1116–1143.
https://doi.org/10.1158/2159-8290.CD-22-0966
Published: 04 May 2023
View article titled, Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer
Open the PDF for Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer in another window
Includes: Supplementary data
Journal Articles

Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib

Ian M. Silverman, Antoine Hollebecque, Luc Friboulet, Sherry Owens, Robert C. Newton, Huiling Zhen, Luis Féliz, Camilla Zecchetto, Davide Melisi, Timothy C. Burn
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2021) 11 (2): 326–339.
https://doi.org/10.1158/2159-8290.CD-20-0766
Published: 02 February 2021
View article titled, Clinicogenomic Analysis of <em>FGFR2</em>-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
Open the PDF for Clinicogenomic Analysis of <em>FGFR2</em>-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib in another window
Includes: Supplementary data
Journal Articles

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer

Satoshi Yoda, Jessica J. Lin, Michael S. Lawrence, Benjamin J. Burke, Luc Friboulet, Adam Langenbucher, Leila Dardaei, Kylie Prutisto-Chang, Ibiayi Dagogo-Jack, Sergei Timofeevski, Harper Hubbeling, Justin F. Gainor, Lorin A. Ferris, Amanda K. Riley, Krystina E. Kattermann, Daria Timonina, Rebecca S. Heist, A. John Iafrate, Cyril H. Benes, Jochen K. Lennerz, Mari Mino-Kenudson, Jeffrey A. Engelman, Ted W. Johnson, Aaron N. Hata, Alice T. Shaw
Journal: Cancer Discovery
Cancer Discov (2018) 8 (6): 714–729.
https://doi.org/10.1158/2159-8290.CD-17-1256
Published: 31 May 2018
View article titled, Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <em>ALK</em> Mutations in ALK-Positive Lung Cancer
Open the PDF for Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <em>ALK</em> Mutations in ALK-Positive Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

Justin F. Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo-Jack, Shirish Gadgeel, Katherine Schultz, Manrose Singh, Emily Chin, Melissa Parks, Dana Lee, Richard H. DiCecca, Elizabeth Lockerman, Tiffany Huynh, Jennifer Logan, Lauren L. Ritterhouse, Long P. Le, Ashok Muniappan, Subba Digumarthy, Colleen Channick, Colleen Keyes, Gad Getz, Dora Dias-Santagata, Rebecca S. Heist, Jochen Lennerz, Lecia V. Sequist, Cyril H. Benes, A. John Iafrate, Mari Mino-Kenudson, Jeffrey A. Engelman, Alice T. Shaw
Journal: Cancer Discovery
Cancer Discov (2016) 6 (10): 1118–1133.
https://doi.org/10.1158/2159-8290.CD-16-0596
Published: 02 October 2016
View article titled, Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <em>ALK</em>-Rearranged Lung Cancer
Open the PDF for Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <em>ALK</em>-Rearranged Lung Cancer in another window
Includes: Supplementary data
Journal Articles

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer

Luc Friboulet, Nanxin Li, Ryohei Katayama, Christian C. Lee, Justin F. Gainor, Adam S. Crystal, Pierre-Yves Michellys, Mark M. Awad, Noriko Yanagitani, Sungjoon Kim, AnneMarie C. Pferdekamper, Jie Li, Shailaja Kasibhatla, Frank Sun, Xiuying Sun, Su Hua, Peter McNamara, Sidra Mahmood, Elizabeth L. Lockerman, Naoya Fujita, Makoto Nishio, Jennifer L. Harris, Alice T. Shaw, Jeffrey A. Engelman
Journal: Cancer Discovery
Cancer Discov (2014) 4 (6): 662–673.
https://doi.org/10.1158/2159-8290.CD-13-0846
Published: 01 June 2014
View article titled, The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
Open the PDF for The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data